2309 GMT - Nufarm's decision to review its Seed Technologies business isn't likely to deliver a good result for shareholders, reckons Jefferies. Nufarm says all options are on the table for Seed Technologies in the UBS-led review. Nufarm has grappled with low fish-oil pricing in recent months, which led it to tell investors that it won't achieve a target of A$100 million of omega-3 revenue in FY 2025. Analyst Ramoun Lazar says the review "is likely to result in subscale outcomes for shareholders, given constrained near-term AquaTerra economics due to poor pricing and suboptimal production cost profile." Jefferies downgrades Nufarm to "underperform," from "hold," and cuts its price target by 55%, to A$1.96/share. Nufarm ended Wednesday at A$2.81. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
May 21, 2025 19:09 ET (23:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.